ons in The
People's Republic of China, variations in cash flow, reliance on
collaborative retail partners and on new product development, variations in
new product development, risks associated with rapid technological change,
and the potential of introduced or undetected flaws and defects in
products, and other risk factors detailed in reports filed with the
Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Yu-bo Hao, Board Secretary
Tel: +86-0451-5399-4069
Email: china_sky_one@yahoo.cn
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Website: http://www.ccgir.com
Mr. Richard Micchelli, Financial Writer
Tel: +1-646-454-4516
Email: richard.micchelli@ccgir.com
Website: http://www.ccgir.com
'/>"/>SOURCE China Sky One Medical, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders2.
tootoo.com: Chinas Farmers Welcome the New Trend of Organic Farming3.
China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification4.
China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%5.
China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII6.
China Biopharma Effects 1 for 100 Reverse Stock Split7.
China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company8.
China Yingxia International, Inc. Appoints New Vice President of Finance9.
China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility10.
China Biologic Products to Present at the SIG Beijing Management Summit11.
China Biologics Production Facility Renews GMP Certification